Akkermansia muciniphila: The Gut Microbe You Can Now Buy

Written by the Nuvirox Research Team

Short answer: Akkermansia has the strongest human trial evidence of any so-called next-generation probiotic, and that evidence is still small, mixed, and heavily dependent on who you already are. Three randomised controlled trials in humans is more than almost any other single-strain product can claim. But the pivotal study had 32 completers, the largest metabolic outcomes were secondary, one trial found nothing across its whole group, and the most consistent finding is that benefit concentrates in people who start with low levels.

What is Akkermansia muciniphila?

It is a bacterium that lives in the mucus layer lining the gut, where it feeds on mucin — the glycoproteins that make up that layer. That is an unusual niche, and it has an interesting implication: rather than depleting the barrier, Akkermansia’s consumption of mucin appears to stimulate its production, potentially thickening the layer it lives in. That barrier is the same one at issue in debates about intestinal permeability.

In healthy adults it can account for a few percent of total gut bacteria. Its abundance is negatively correlated with overweight, obesity, untreated type 2 diabetes and hypertension across multiple human observational studies. In animal models of obesity — both diet-induced and genetic — reduced Akkermansia abundance appears alongside increased adiposity, greater hepatic and adipose inflammation, hyperglycaemia, insulin resistance and dyslipidaemia.

Why does the dead version work better?

This is the strangest thing in the literature and worth explaining properly. Akkermansia is an anaerobe and oxygen-sensitive, with demanding growth requirements — which made it impractical to manufacture and administer to humans. Researchers therefore tested pasteurisation, a mild heat treatment (30 minutes at 70 °C), expecting it to reduce or eliminate the effect.

It did the opposite. In mice, pasteurisation did not abolish the metabolic benefit but appeared to enhance it. The leading explanation is that the active component is a specific outer membrane protein, and heat treatment either exposes it or stabilises it in a more available form — meaning the bacterium does not need to be alive or to colonise at all. Whatever the mechanism, the practical consequence is enormous: a heat-stable, non-viable product is vastly easier to manufacture, store and standardise than a living anaerobe.

The pasteurisation finding is what turned Akkermansia from a research curiosity into a commercial product.

What human studies actually show

The pivotal trial is genuinely positive on metabolic markers and weak on body composition. Depommier and colleagues, publishing in Nature Medicine in 2019 (NCT02637115), enrolled 40 overweight or obese insulin-resistant volunteers; 32 completed. Participants took 10¹⁰ live or pasteurised Akkermansia, or placebo, daily for three months. Compared with placebo, pasteurised Akkermansia improved insulin sensitivity by 28.62 ± 7.02% (P = 0.002), reduced insulinaemia by 34.08 ± 7.12% (P = 0.006) and lowered total cholesterol by 8.68 ± 2.38% (P = 0.02). It also reduced markers of liver dysfunction and inflammation. Body weight fell by 2.27 ± 0.92 kg — but at P = 0.091, which does not reach significance, and the same applied to fat mass and hip circumference. The overall gut microbiome structure was unaffected.

A larger and more recent trial supports weight maintenance. A controlled randomised trial published in Nature Medicine in 2026 enrolled 90 adults with overweight or obesity who underwent an 8-week low-energy diet achieving at least 8% weight loss, then 24 weeks of ad libitum eating with daily pasteurised Akkermansia MucT or placebo. Weight regain was lower on MucT (1.2 ± 0.7 kg versus 3.2 ± 0.4 kg, P = 0.012), and net weight loss from baseline was greater by 3.1 ± 0.7 kg (P = 0.009). No serious treatment-related adverse events occurred. Critically, initial Akkermansia abundance was associated with cardiometabolic response.

Now the counterweight, and it is important. A 12-week randomised, double-blind, placebo-controlled trial in 58 participants with overweight or obese type 2 diabetes tested Akkermansia (AKK-WST01) against placebo alongside routine lifestyle guidance. Both groups showed decreases in body weight and HbA1c — without significant between-group differences. The apparent benefits emerged only on subgroup analysis: participants with low baseline Akkermansia showed high colonisation efficiency and significant reductions in body weight, fat mass and HbA1c, while those already replete saw little. Subgroup findings after a null primary result are hypothesis-generating, not confirmatory, and should be read that way.

What Akkermansia won’t do

It will not act as a weight loss product. The pivotal trial’s weight change did not reach statistical significance, and the 2026 trial studied weight loss maintenance after a supervised low-energy diet — a specific and different question. Anyone marketing it as a fat burner is describing results the trials did not produce.

It also will not do much if your levels are already adequate, which is the clearest consistent signal across the trials and the least commercially convenient. Both the type 2 diabetes trial and the 2026 maintenance trial found response depended on baseline abundance. There is no accessible consumer test that reliably reports your Akkermansia level in a way that would let you predict this.

And the trials are small. Thirty-two completers, 58 participants, 90 participants. Compared with most probiotic marketing this is impressive; compared with the standard of evidence for a metabolic intervention it is preliminary.

Dosing, and what the trials actually used

The dose used in the pivotal human study was 10¹⁰ bacteria per day, pasteurised, taken every morning on an empty stomach, for three months. That is the figure commercial products generally reference. Duration matters: the metabolic changes were measured at three months, and the maintenance trial ran 24 weeks. This is not a short experiment.

Safety was consistently good. The 2019 study reported the intervention was safe and well tolerated at the highest dose tested. The 2026 trial reported no serious treatment-related adverse events. That is a reasonable record for three trials, though it is still three trials.

A more accessible alternative worth mentioning: dietary fibre, particularly polyphenol-rich foods, is associated with higher Akkermansia abundance in observational work. That route has not been tested against the supplement head to head, but it costs nothing and has independent evidence behind it. Chronic low-grade inflammation is one of the proposed links between gut composition and how you feel day to day, which we cover in inflammaging. The same general logic applies across most of the microbiome-supplement category, and it is a useful default when the trial evidence is this thin.

Frequently asked questions

Should I take Akkermansia if my metabolic markers are normal?

The trials enrolled people with insulin resistance, overweight or type 2 diabetes. There is no evidence in metabolically healthy people, and the baseline-dependence findings suggest benefit would be smaller or absent in someone whose levels are already adequate.

Why is the pasteurised form better than the live one?

The leading explanation is that the active component is a specific outer membrane protein that survives — and may be made more available by — mild heat treatment, meaning live colonisation is not required. In the pivotal trial it was the pasteurised arm that produced the clearest metabolic improvements.

Can I raise Akkermansia through diet instead?

Fibre and polyphenol-rich foods are associated with higher abundance in observational studies. This has not been directly compared with supplementation in a trial, but it is a low-cost approach with well-established independent benefits.

How long before anything happens?

The human trials measured outcomes at three months and 24 weeks. Nothing in this literature supports expecting a change in weeks.

Is it safe long-term?

Three human trials reported good tolerability with no serious treatment-related adverse events, over three to six months. Longer-term safety data in larger populations does not yet exist, which is worth knowing before treating it as indefinite.

From Nuvirox

Why we formulated NAD+ Restore

Akkermansia and NAD+ address different systems entirely — one is a gut microbial intervention, the other a metabolic coenzyme pathway. We built NAD+ Restore around the specific step where the human trial evidence is most consistent: oral nicotinamide riboside reliably raises NAD+ at doses within the published trial range.

• 500 mg nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
• 150 mg trans-resveratrol (Japanese knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
• 10 mg galactomannans from fenugreek — to support absorption.
• 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

Akkermansia is the most credible product in the next-generation probiotic category, which says as much about the category as about Akkermansia. Three randomised trials, real improvements in insulin sensitivity and cholesterol, a genuine weight-maintenance result, and good tolerability — set against 32 completers in the pivotal study, a null primary outcome in the diabetes trial, non-significant weight change, and repeated evidence that benefit depends on your starting abundance. The fair reading is: promising, better-evidenced than almost anything on the same shelf, and nowhere near settled.

References

1. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019. PMID: 31263284. PMCID: PMC6699990. DOI: 10.1038/s41591-019-0495-2. ClinicalTrials.gov NCT02637115.
2. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: efficacy depends on its baseline levels in the gut (12-week RCT, n = 58). PMID: 39879980.
3. Pasteurized Akkermansia muciniphila Muc^T for weight loss maintenance in people with overweight and obesity: a controlled randomized trial (n = 90). Nat Med. 2026. DOI: 10.1038/s41591-026-04394-7.
4. Akkermansia and weight maintenance. ClinicalTrials.gov NCT05417360.
5. Safety and efficacy of a synbiotic formulation containing Akkermansia muciniphila Akk11 on gut microbiota and metabolic health: a randomized controlled trial. Ann Microbiol. 2026. DOI: 10.1186/s13213-025-01839-1.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.